Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026
Flatiron Health announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 – June 2, 2026, in Chicago, Illinois. Flatiron’s high-quality real-world data and innovative research capabilities are featured across 25+ research acceptances, including 14 Flatiron-authored poster presentations and online publications.
Flatiron’s presence at ASCO 2026 closely follows the launch of Flatiron Telescope, a multi-agent adaptive analytics platform designed to help life sciences teams find the right patients faster, assess study feasibility in real time, and generate oncology insights on demand. Flatiron Telescope will be demonstrated at the company’s booth (#21149) for attendees to build and iterate on patient cohorts using natural language and generate insights in real time.
Our presence at ASCO 2026 proves that innovation and rigor aren’t at odds—they reinforce each other,” said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. “From digital twins that simulate patient outcomes to LLM-enabled treatment pattern analysis, our work demonstrates that Flatiron is defining—not just participating in—the evolution of oncology evidence. These 25+ acceptances showcase our unified, global oncology engine and reinforce our position as the gold standard in oncology intelligence, trusted to guide the highest-stakes decisions across the industry.
Research highlights include:
- Digital twin modeling for treatment prediction: validating novel counterfactual prediction approaches in NSCLC using clinical trial data, demonstrating how AI-enabled simulation can move beyond observational analysis to model patient outcomes under different treatment scenarios
- Physician adoption of landmark clinical trial findings: a large-language model-based analysis documenting how ASCO plenaries translate to clinical decision-making in real-world practice, the largest such analysis of clinician-patient trial discussions to date
- Recurrence risk prediction in early breast cancer: leveraging multi-site observational data to build predictive models for early breast cancer populations, showing how scale enables discovery in underrepresented patient groups
- Post-operative circulating tumor DNA as a prognostic indicator: examining ctDNA’s role in identifying high-recurrence risk in muscle-invasive and locally advanced bladder cancer, demonstrating the value of real-world biomarker data in routine practice
- Real-world treatment patterns in platinum-resistant ovarian cancer: analyzing platinum re-challenge outcomes in a population with limited evidence guidance, highlighting how Flatiron’s depth of longitudinal data reveals clinical practices that diverge from trial design and guidelines
Join Flatiron Health at booth #21149 for a demo of Flatiron Telescope and follow Flatiron Health on X and LinkedIn for more updates from #ASCO26.
About Flatiron
Flatiron Health transforms cancer care and research through a unified, global oncology engine powered by expert-validated AI and deep clinical and scientific expertise. Built from the experiences of millions of patients across the US, UK, Germany, and Japan, our real-world evidence informs the research, regulatory, commercial, and treatment decisions shaping oncology today. In the US, our point-of-care technology empowers clinicians to deliver smarter, more connected care while generating deeper insights that help advance cancer research.
Source link: https://www.businesswire.com/
